콘텐츠로 건너뛰기
주식/증권 📈 긍정적

Moderna Rallies 8% on 2026 Melt-Up Momentum Even While BioNTech and Merck Stay Flat

요약

Moderna just surged 8% on a morning when its closest cancer-vaccine peer barely budged and its own pipeline partner slipped into the red, and no announcement, trial readout, or analyst call explains why.